Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Penelope MacRae
A major Indian health insurance provider is pushing hospitals to prescribe no-name generic medicines – a move that if adopted industry-wide could potentially lower patient bills, reduce insurance payouts, cut premium rates and help address glaring challenges around healthcare financing in the country.
Dr. Reddy’s Laboratories, India’s second-largest drug firm by sales, has warned that its key US export market remains “unpredictable” after reporting a lower than expected fourth-quarter net profit that capped a tough year.
India’s prime minister has declared that doctors should prescribe medicines using only non-proprietary generic names in an effort to reduce medical bills, but the medical fraternity says the move could jeopardize patient safety, while hurdles mean others see only limited pharma industry impact in the short term.
India’s biggest biotech firm has said it is “cautiously optimistic” about its performance this financial year after fourth-quarter net profit slid due to an exceptional item in the previous year, but reports progress on multiple fronts for its large biosimilar portfolio.
Religare Enterprises, led by Indian tycoons Malvinder and Shivinder Singh who are locked in a bitter arbitration battle with Daiichi Sankyo, has sold off its health insurance unit as it seeks to pare debt and focus on core financial services, in a move the brothers’ lawyers say is designed to raise capital.
India’s Hilleman Laboratories, in partnership with a government agency, expects to start human trials this year with a pioneering multivalent vaccine to prevent shigellosis, a highly contagious bacterial diarrheal disease that is a major killer of children in low-income countries but has proven a difficult vaccine target.